GLOBEALERT
HEALTHLOWSep 8 · Sep 8, 2026, 12:03 PM

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

CNBC · global

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

More in Health